



HAL
open science

Physicochemical and Microbiological Stability of a New Oral Clonidine Solution for Paediatric Use

Camille Verlhac, Damien Lannoy, Florence Bourdon, Marie Titecat, Emilie Frealle, Carole Nassar, Christophe Berneron, Pascal Odou

► To cite this version:

Camille Verlhac, Damien Lannoy, Florence Bourdon, Marie Titecat, Emilie Frealle, et al.. Physicochemical and Microbiological Stability of a New Oral Clonidine Solution for Paediatric Use. *Pharmaceutical Technology in Hospital Pharmacy*, 2018, *Pharmaceutical Technology in Hospital Pharmacy*, 3 (2), pp.79-90. 10.1515/pthp-2018-0006 . hal-02148628

HAL Id: hal-02148628

<https://hal.univ-lille.fr/hal-02148628v1>

Submitted on 5 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF A NEW ORAL CLONIDINE SOLUTION FOR PAEDIATRIC USE

| | |
|------------------|--|
| Journal: | <i>Pharmaceutical Technology in Hospital Pharmacy</i> |
| Manuscript ID | PTHP.2018.0006.R1 |
| Manuscript Type: | Research Article |
| Classifications: | New pharmaceutical formulation, Non-sterile compounding, Oral formulations, Paediatric formulations, Stability testing |
| Keywords: | clonidine, pharmaceutical solution, drug stability, paediatrics |
| | |

SCHOLARONE™
Manuscripts

View Only

Stability of oral clonidine solution for paediatric use

1
2
3 **PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF A NEW ORAL**
4 **CLONIDINE SOLUTION FOR PAEDIATRIC USE**
5

6 C Verlhac¹, D Lannoy^{1,2}, F Bourdon¹, M Titecat³, E Frealle⁴, C Nassar¹, C Berneron¹, P
7 Odou^{1,2}
8

9 1 CHU Lille, Institut de Pharmacie, F-59000 Lille, France

10 2 Univ. Lille, EA 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les
11 Technologies Associées, F-59000 Lille, France

12 3 CHU Lille, Laboratoire de Bacteriologie - Hygiène, F-59000 Lille, France

13 4 CHU Lille, Laboratoire de Parasitologie - Mycologie, F-59000 Lille, France
14
15
16

17 Corresponding author:
18

19 Dr Damien Lannoy
20

21 Laboratoire de Biopharmacie, Pharmacie Galénique et Hospitalière
22

23 EA 7365 Groupe de Recherche sur les formes injectables et les Technologies Associées
24 (GRITA)
25

26 Faculté de Pharmacie
27

28 3 Rue Professeur Laguesse
29

30 59006 Lille Cedex
31

32 damien.lannoy@univ-lille2.fr
33

34 Tel : +33 (0)3 20 96 40 29
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF A NEW ORAL CLONIDINE SOLUTION FOR PAEDIATRIC USE

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

Abstract

Background: As many drugs are unavailable for paediatric use, hospital pharmacies are often required to develop suitable formulations themselves. Clonidine is commonly used in paediatrics (in severe hypertension, in opiate withdrawal syndrome, in tics and Gilles de la Tourette syndrome or in anaesthetic premedication) but no appropriate formulation has been drawn up.

The aims of this work were to develop an oral solution of clonidine dedicated to children and to assess its physicochemical and microbiological stability.

Methods: Formulation of an oral solution of clonidine hydrochloride **suitable for neonates and paediatrics** was developed using the active pharmaceutical ingredient (API), with as few excipients as possible **and without any complex excipient vehicle**. A stability study was made according to GERPAC-SFPC guidelines. At each point in time (D0, D1, D7, D15, D29, D60 and D90), visual aspect (limpidity), pH and osmolality were established. Clonidine concentration was quantified using a stability-indicating HPLC-UV-DAD method previously developed from a forced degradation study and validated according to SFSTP Pharma. Microbiological stability was also tested according to the European Pharmacopeia monograph with the best adapted method (by comparing membrane filtration and inclusion). Solutions were stored in amber glass bottles with an oral adapter for up to 3 months in two different conditions: **5°C +/- 3°C and at 25°C +/- 2°C** with 60% residual humidity (climatic chamber).

Results: The formulated oral solution is composed of API at a concentration of 10 µg/mL and of potassium sorbate (0.3%), citric acid, potassium citrate (pH 5 buffer) and sodium saccharine (0.025%). Forced degradation highlighted six degradation products and the method was validated in the acceptance limits of ± 5%. On D29, the mean percentages of the initial clonidine concentrations (+/-standard deviation) were 92.95+/-1.28% in the solution stored at **25°C +/- 2°C** and 97.44+/-1.21% when stored **at 5°C +/- 3°C**. On D90, means were respectively 81.82+/-0.41% and 93.66+/-0.71%. The visual aspect did not change. Physical parameters remained stable during the study: pH varied from 4.94 to 5.09 and osmolality from 82 to 92 mOsm/kg in the two conditions tested here. Membrane filtration appeared to be the more sensitive method. Whatever the storage conditions, <1 micro-organism/mL was identified (only environmental) with no detected *E.coli*.

Conclusions: This formulation is stable for at least 3 months at **5°C +/- 3°C** in amber glass bottles and for one month when stored at room temperature. Microbiological stability was proven in accordance with the European Pharmacopeia.

Stability of oral clonidine solution for paediatric use

Keywords: clonidine, oral solution, drug stability, pediatric preparation

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

Introduction

Among drugs available on the European market, only a few have a formulation or dosage adapted to paediatric use. In this context, off-label drug use is frequent. In hospital, it is estimated to vary from 11% to 80% [1] due to the absence of paediatric clinical trials or adapted formulations for children. In 2006, a European regulation [2] encouraged pharmaceutical industries to develop specific paediatric formulations [3]. As **they are still lacking**, hospital pharmacies are required to develop and prepare paediatrically-adapted forms [4].

Clonidine is a partial agonist of the alpha2 **adrenergic receptors** and central imidazoline receptors. Pharmacologically, it acts centrally to reduce sympathetic tone, resulting in a fall in diastolic and systolic blood pressure and a reduction in heart rate [5]. In the adult population, clonidine is licenced for the treatment of hypertension. In paediatrics, clonidine is frequently used, still off-label, in paediatric intensive care and anaesthesia. It has been used in attention-deficit hyperactivity disorder associated with methylphenidate, in opiate withdrawal syndrome in newborn infants [6-8], or in tics and Gilles de la Tourette syndrome [9]. Other uses are as an analgesic in neuropathic pain, in continuous epidural infusion or in severe non-treatable oncologic pain, combined with opiates [10]. Clonidine has also been considered for children in premedication before anaesthesia, rather than midazolam, because of potentially better post-operative analgesia [11].

The marketed formulations in Europe are tablets (25 µg), ampoules for injection (150 µg/1 mL) and transdermal patches providing between 0.1 and 0.3 mg of clonidine per day. Tablet formulation is not suitable for paediatric use (especially under six years of age) [12], as swallowing tablets is unsafe or impossible, and is not a flexible form for dose adjustment [13]. Furthermore, the recommended therapeutic range of clonidine in children implies grinding tablets, which increases the risk of dose imprecision. In this population, solution is the most acceptable pharmaceutical form [14]. Some formulations have already been specifically developed to obtain suitable liquid forms [15-20]. The number and proportion of excipients must be as low as possible as risks about certain excipients, especially ethanol, propylene glycol, benzyl alcohol and parabens have been identified [21-25]. **These excipients are sometimes found in ready-to-use commercial complex excipient vehicles (for example, parabens in Ora®) which are still not available worldwide, are subject to shortages, and their composition is susceptible to modification. Quality control for these vehicles in hospital pharmacies do not correspond to compendial methods.**

Therefore, the aim of this study was to develop **with raw materials**, a paediatric formulation of clonidine hydrochloride without any identified risks for children and to evaluate its

Stability of oral clonidine solution for paediatric use

physicochemical and microbiological stability in two different conditions (storage at room temperature and at $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$).

Materials and Methods

Materials:

Clonidine hydrochloride, citric acid monohydrate (Inresa, Bartenheim, France), tripotassium citrate, potassium sorbate and sodium saccharin (Cooper, Melun, France) used in the formulation were of pharmaceutical quality. Sterile water (Fresenius Kabi, Sevres, France) was used as solvent.

Acetonitrile, potassium dihydrogen phosphate, sodium hydroxide and 37% hydrochloric acid were supplied by VWR (Fontenay-sous-bois, France). 30% hydrogen peroxide was purchased from Cooper (Melun, France). Potassium hydrogen phosphate was obtained from Merck (Darmstadt, Germany). Clonidine hydrochloride was supplied by CRS European Pharmacopoeia. All reagents used were at least of analytical grade except acetonitrile and water which were HPLC grade.

Formulation:

All compounding steps were carried out in a dedicated non-classified zone, without any specific protection, according to National Good Compounding practices. The operator respected the regulatory hygiene protocol for clothing (surgery mask, gloves, gown and cap) and hand-washing.

Solutions of $10\mu\text{g/mL}$ clonidine hydrochloride (HCl) were prepared in two steps. First, a solution of 1mg/mL clonidine HCl was made by dissolving 50 mg Clonidine HCl in 50 mL of sterile water.

The final solution was then obtained by dissolving 200 mg of citric acid monohydrate and 346 mg of potassium citrate in water to obtain a pH value of 5. Once the components were dissolved, 300 mg potassium sorbate and 26 mg sodium saccharine were added. Finally, 1 mL of 1 mg/mL solution and water were added to reach a volume of 100 mL.

Final solutions were stored in amber type II glass bottles with Low Density Poly Ethylene (LDPE) white oral adapter (Baxter, USA), and an LDPE stopper.

One batch of 66 vials of 15 mL was prepared on day 0.

Stability of oral clonidine solution for paediatric use

Chromatographic conditions

The chemical stability of the Clonidine HCl solution was assessed using an HPLC method consisting of a ThermoFisher Ultimate 3000 system (Villebon-sur-Yvette, France). Separation was obtained using a C18 HyperSil Gold guard column (10x3mm, 3µm) and a C18 HyperSil Gold column (100x3mm, 3µm) conditioned at 40°C. The mobile phase was composed of a mixture of acetonitrile and phosphate solution (25mM, pH=4.5) (5/95 v/v). The injection volume was 10 µL and the flow rate 0.5 mL/min. UV detection was performed at 210 nm with a DAD system (DAD 3000).

Development of stability-indicating method

Forced degradation was performed to ensure complete separation between clonidine, excipients and clonidine degradation products. Thus, Clonidine HCl was stressed in acidic, alkaline, oxidative and neutral hydrolytic conditions according to the GERPAC-SFPC standard [26]. One volume of a 400 µg/mL clonidine solution was mixed with one volume of 5N HCl, 5N NaOH and 30% hydrogen peroxide in turn, prior to being heated at 100°C for up to 3 days. Samples were then withdrawn at several times, and diluted to 100 µg/mL, taking care to neutralise media before injection, in an attempt to obtain a 20% decrease in the main active ingredient. For each sample, the UV spectrum was analysed with the PDA detector to highlight the possible appearance of new peaks and clonidine peak decreases. Method specificity was assessed by comparing chromatograms of stressed clonidine solutions with a standard clonidine solution and with a blank solution spiked with excipients.

Validation method

The validation method was carried out according to the validation guidelines established by the French Society of Pharmaceutical Sciences and Techniques – SFSTP pharma [27-30]. Each day and for three consecutive days, five calibration standard sets and three sets of 4 validation standards were prepared from 10 µg/mL independent aqueous clonidine solutions with appropriate dilutions in the mobile phase to obtain a calibration range at 1.5; 2; 2.5; 3 and 3.5 µg/mL and 4 validation standard levels at 1.75; 2.25; 2.75; 3.25 µg/mL. A preliminary study of the absence of matrix effect had been made.

The Limit Of Quantification (LOQ) and Limit Of Detection (LOD) according to the International Conference on Harmonization (ICH) [31] were calculated respectively as the

Stability of oral clonidine solution for paediatric use

ratios $10 \times \sigma N/S$ and $3.3 \times \sigma N/S$ where σN is the standard deviation of the noise obtained with six blanks and S , the slope of the calibration curve. Selectivity, response function linearity, trueness, precision (repeatability and intermediate precision) were studied according to the validation requirements of the SFSTP and accuracy profile was assessed by taking into account the $\pm 10\%$ acceptance limits for quantification (maximum tolerated error), an alpha risk of 5% and β expectation tolerance limits ($\beta = 95\%$).

Physico-chemical stability study:

Samples were stored in amber glass bottles, protected from light in two different storage conditions:

- at $25^\circ\text{C} \pm 2^\circ\text{C}$, with 60% residual humidity (climatic chamber) and,
- at $5^\circ\text{C} \pm 3^\circ\text{C}$.

On the day of the analysis, two samples were tested twice for each condition to limit variability. Parameters were measured on days 0, 1, 7, 15, 30, 60, 90 and 120.

Vials were stored protected from light and horizontally so that all the conditioning materials were in contact with the solution.

At each point in time, the percentage of the remaining clonidine HCl concentration was compared to the concentration at T0 and the four validation standards were analysed. Stability was defined as a percentage of at least 90% of the initial clonidine HCl concentration.

Physical parameters such as colour, odour, limpidity, osmolality and pH value were measured.

At each sampling time, the pH was measured three times in two vials with an HI223 HANNA Instrument pH-meter (Tannerries, France).

The osmolality of a vial was measured using an Advanced Micro Osmometer® Model 3300 (Series 03010058P, Advanced Instruments, Norwood, USA).

Again the measurement was repeated three times for the two vials. Statistical analysis on osmolality and pH was made at different times with the Kruskal Wallis test (alpha risk of 0.05).

Stability of oral clonidine solution for paediatric use

1
2
3 Finally, at each sampling time, and for each storage condition, a visual inspection of the vial
4 was made by the same operator for the appearance of colouring, blurring, haze, particles,
5 gas or precipitate.
6
7
8

9
10 *Validation of microbial recovery method for bacteria and fungi*

11
12 As the formulated solution is designed for the oral route, sterility is not necessary but the
13 absence of contamination has to be validated.
14

15
16 A study of the artificial microbiological contamination of the solution was conducted, adapted
17 from 5.1.4 “microbiological quality of non-sterile pharmaceutical preparations and substances
18 for pharmaceutical use”, 2.6.12 “microbiological examination of non-sterile products:
19 microbial enumeration tests” and 2.6.13 “microbiological examination of non-sterile products:
20 tests for specified micro-organisms” monographs in the EP [32-34].
21
22

23
24 The preservative effect of potassium sorbate was neutralised by diluting the clonidine
25 solution with pH 7.2 phosphate buffer (1:10), and by increasing its pH to over 6 [33-35].
26

27
28 Reference strains (*Staphylococcus aureus* ATCC 29213, *Escherichia coli* ATCC 25922,
29 *Aspergillus brasiliensis* ATCC 16404, *Candida albicans* ATCC 10231) were used for
30 neutralisation tests.
31

32
33 Briefly, micro-organisms isolated from agar plates were resuspended in sterile phosphate
34 saline buffer. Serial dilutions of bacterial and fungal suspensions were made to obtain
35 standardised microbial suspensions of 10^3 micro-organisms/mL. 5 mL of the suspensions
36 were then added to 45 mL of the studied solutions (i.e. pure clonidine, 1/10 diluted clonidine
37 and neutralising buffer), yielding 10^2 micro-organisms/mL suspensions.
38
39
40

41
42 Validation of microbial recovery was carried out by comparing the inclusion and filtration
43 methods recommended by EP guidelines. On the one hand, 1 mL of the 10^2 micro-
44 organisms/mL suspensions was covered by 19 mL of agar medium. After solidification, the
45 agar plates were incubated at 37 °C (bacteria) or 30°C (fungi). On the other hand, 10 mL of
46 the 10^2 micro-organisms/mL suspensions was filtered through 0.45 μ m membranes
47 (Millipore, Billerica, USA) rinsed or not with 5 ml of pH 7.2 phosphate buffer. Membranes
48 were set on appropriate agar media: Chapman and Tergitol (Oxoid, Wesel, Germany) for *S.*
49 *aureus*, and *E. coli*, respectively, and Sabouraud for *C. albicans* and *A. brasiliensis*.
50
51
52
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

Microbiological count was made after an incubation period of three days at 37°C for bacteria and five days at 30°C for fungi.

Fertility tests were made beforehand for all agar plate media.

Each experiment was performed in duplicate.

Analysis of the data

The efficacy of neutralisation was considered for a microbial recovery ratio > 0.5 between the neutralised solution and the negative control.

Microbiological quality control study

Analysis was performed on clonidine solutions stored for 75 days at room temperature or 5°C +/- 3°C. The results were interpreted according to EP requirements for oral aqueous preparations which are: total aerobic microbial count (TAMC) of less than 100 CFU/mL, total combined yeast and moulds (TYMC) of less than 10 CFU/mL and absence of *E. coli* [32].

Each studied solution was diluted at 1:10 with phosphate buffer pH = 7.2.

Ten milliliters of the diluted solutions were then filtered on 0.45 µm membranes rinsed with 5 mL of phosphate buffer. The membranes were then set in duplicate on PCA, Chapman, Tergitol or Sabouraud media. Agar plates were incubated for 3 days at 37°C for bacteria and 5 days at 30°C for fungi. Identification of bacterial colonies was made through MALDI TOF mass spectrometry (Brüker, Wissembourg, France).

Results

Validation of the stability-indicating method

The specificity of the method was assessed between clonidine and excipients (figure 1) and clonidine and degradation products (figure 2). With these elution conditions, complete separation between Clonidine and excipients (figure 1a) and a convenient clonidine retention time (around 6 min) were obtained (figure 1b). The stress degradation study led to the formation of degradation products, of which six were detected at the following retention times: 2.9 – 3.4 – 4.2 - 6.5 – 7.6 and 10.9 min. Degradation peaks appeared in the 3 conditions (acid, alkaline and oxidative) but there was a 20% reduction in clonidine only in alkaline media (figure 2). A comparison of chromatograms indicated the absence of co-

Stability of oral clonidine solution for paediatric use

1
2
3 elution between the degradation products, clonidine and excipients and ensured the
4 specificity of the method (figures 1 and 2).
5

6
7 LOD and LOQ were 0.07 µg/mL and 0.21 µg/mL, respectively. The response function
8 obtained by using the calibration curves was $y = 1.8762x + 0.0406$ and the determination
9 coefficient (R^2) of over 0.999 attested to the validity of the model. Linear models ($R^2 > 0.995$)
10 were obtained by plotting the introduced concentration to the back-calculated concentration;
11 the slope close to one and y-intercept approaching zero showed the linearity of the method.
12 The accuracy profile displayed in figure 3 shows a tolerance interval included within the
13 acceptance limits of $\pm 5\%$ and so respects acceptance criteria set at $\pm 10\%$. Consequently,
14 the method was able to quantify clonidine from 1.5 to 3.5 µg/mL with a total error of $\pm 5\%$ and
15 an alpha risk of 5%.
16
17
18
19
20
21
22

23 *Physico-chemical stability*

24
25 Table 1 shows the percentage of initial concentration \pm SD of clonidine HCl remaining on
26 each day, for the two storage conditions. A solution stored at 25°C \pm 2°C was stable for one
27 month whereas one stored at 5°C \pm 3°C was stable for at least 3 months.
28
29

30 An unidentified product appeared on the chromatogram (Tr: 2.9 min) at 2 months,
31 corresponding to none of the components in the formulated solution when stored at 25°C.
32
33

34 Osmolality and pH were also measured and are presented in Table 2. No statistical change
35 in pH value was observed during the study. Even if a statistical difference is found in
36 osmolality, threshold or link with the degradation process is unclear. No change in colour,
37 odour or limpidity was observed.
38
39
40

41 *Validation of microbial recovery method for bacteria and fungi*

42
43 Results are presented in Tables 3 and 4 for bacteria and fungi respectively.
44

45 In all samples, bacterial and fungal load was inferior to 100 UFC/mL with similar values
46 between the positive (pure clonidine) and the negative (phosphate solution at pH 4.5)
47 controls. All micro-organisms grew, regardless of the method. Although slightly higher
48 recovery rates were observed with the inclusion method for some organisms (*i.e.* *E. coli* and
49 *C. albicans*), lower bacterial or fungal concentrations are to be expected in the clonidine
50 suspension and larger volumes should be used to increase sensitivity. However, in this
51 experiment, the filtration method was not adapted to *A. brasiliensis* numeration owing to a
52 rapid confluence of the colonies. In any case, the additional step of membrane washing did
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

not alter the final microbiological count, enabling the elimination of residual preservative components. In these experiments, membrane filtration appeared as a sensitive and appropriate method for highlighting low bacterial or fungal concentrations. Hence, this method was chosen for further quality control assessment.

Microbiological quality control study

When assessing microbial contamination after 75 days' storage at room temperature or at +2-8°C, bacterial counts varied between 1 and 25 CFU in both. No fungal colony was found after filtering the neutralised clonidine solution (Table 5). Mass spectrometry identification performed on bacterial colonies indicated environmental or cutaneous species (*Micrococcus* sp., coagulase negative *staphylococci*, *Methylbacterium* sp., *Bacillus* sp.). It is important to note that no *E. coli* was detected in any sample. These results were in accordance with EP thresholds.

Discussion

To the best of our knowledge, this is the first description of a ready-to-administer oral clonidine solution, compounded without any parabens or any complex excipient vehicle, adapted to children and stable for at least 3 months.

Most formulations use clonidine tablets as raw materials [16-19]. Clonidine powder is more accurate and reduces the variability of tablet sourcing. Preparing in conditions as described above eliminates the introduction of microbiological contamination, although it is necessary to validate this data in the specific compounding location. Adding an antimicrobial preservative to an aqueous-based oral solution contained in a multi-dose vial is mandatory. Potassium sorbate appears to be the candidate of choice, as it does not cause any side effects and its concentration in the solution is higher than the minimal inhibitory concentration (MIC) for some bacteria (*E. coli* and *S. aureus*) and fungi [35]. To be effective, it is necessary to add a buffer to adjust pH to around 5; citrate buffer was chosen because of its good tolerance when used orally, but it can modify the taste [3] and so a sweetener was added to the solution.

Neither sugar nor dextrose was added, because of cariogenic or metabolic risk; furthermore, they potentially increase the osmolality and viscosity of the solution. The taste of similar solutions, with various saccharin concentrations, and without clonidine, was assessed by a group of adult volunteers and led to using the lowest concentration tested (0.025%). The

Stability of oral clonidine solution for paediatric use

1
2
3 solution is now regularly dispensed in the wards of our hospital and accepted without
4 complaints.
5

6 Two clonidine liquid formulations dedicated to paediatrics have previously been developed,
7 without parabens [19-20]. Sauberan *et al.* [19] reported a liquid oral form at 20 µg/mL with
8 simple syrup NF as vehicle, stable for 35 days. This compounded liquid form was highly
9 osmolar, at around 3180 mOsm/kg, tenfold higher than what is physiologically acceptable;
10 this justified, according to Sauberan *et al.*, diluting it with breast milk, without establishing its
11 stability or acceptability in this context. Simple syrup in Europe generally contains parabens
12 as preservatives [15].
13

14 Potier A *et al.* [20] developed a clonidine liquid formulation dosed at 10 µg/mL, compounded
15 with inorpha°, a complex excipient vehicle, available firstly in France. This excipient vehicle
16 has many advantages, for example it is alcohol- and paraben-free. Also, data increasingly
17 shows its advantages such as convenience in compounding liquid forms, with microbiological
18 and chemical stability for various APIs. However, it is not available worldwide, is susceptible
19 to composition alterations and its impact on the compounded forms of API is unknown.
20

21 Inorpha° supplies have recently been disrupted, which is potentially detrimental to paediatric
22 patients. Furthermore, some raw materials are not well defined in terms of pharmaceutical
23 quality, such as taste-masking agents. All these reasons have led us to conclude that the
24 formulation we develop is useful in practice, is easy to implement and it is available. Our data
25 indicates longer stability between +5 +/- 3°C (at least 90 days, when stocked) compared to
26 60 days for Potier *et al.* They showed however that the concentration of sorbate potassium,
27 similar to our formulation, is physico-chemically stable.
28

29 Potier *et al.* [20] hypothesised that degradation at ambient temperature is potentially due to
30 an adsorption on the PET container. As we use glass for containers and reach a similar
31 decrease (86.8% of initial concentration vs 84.1% for Potier A *et al.*), the degradation of
32 clonidine is due to another phenomenon that should be investigated.
33

34 Other developed formulations appear to be stable for 9 months at ambient temperature. The
35 origin of instability needs to be studied, and hypotheses to be explored are concentration, pH
36 or interaction with excipients. Injectable solution specialties dosed at 150 µg/mL clonidine
37 with extensive stability are at a pH of 4 whereas the pH of our oral solution is around 5. It
38 was not possible to buffer the solution at pH 4 because of blurring and physical change. A
39 formulation dosed at 50µg/mL and with methylparaben, expiring at 9 months is at pH 5 [15].
40 It is also necessary to identify, by an adapted analytical method (nuclear magnetic
41 resonance, mass spectrometry), the substance that induced a peak (previously mentioned)
42 during a forced degradation study and increased during a stability study. Thus the
43 mechanism of formation should be studied, and potentially reduced.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stability of oral clonidine solution for paediatric use

Several forced degradation studies have already been reported [18, 20, 36-38]. However none have highlighted degradation products, notably those indicating a loss of clonidine. Our results describing 6 degradation products can be explained by our weaker eluting analytical conditions which were able to detect polar degradation products. Moreover, degradation product detection was improved with drastic stress conditions and a concentrated clonidine solution at 100 µg/mL.

Other HPLC stability-indicating methods have previously been developed [15-18, 20, 39-41], usually with ammonium salt and methanol as mobile phase. In these methods, the sample is often centrifuged before analysis, especially when using complex vehicles in formulations or when formulating suspensions. The simplicity of our formulation meant we did not have to filter samples. Indeed, we have shown that filtration induces a potential adsorption of clonidine on the media.

The validation method according to SFSTP is based on the study of « accuracy », also called « total error » which results from the sum of systematic error (trueness) and random error (precision) obtained with validation standards. The total error of the analytical method is represented by an accuracy profile indicating total error according to the concentration level of the validation standard studied. The accuracy profile is therefore a decision-making tool ensuring the quality of the analytical procedure with a tolerance error (acceptance limits) and a risk (β -expectation tolerance interval) previously defined by the analyst. Hence, β represents the probability that measurements are included within the acceptance limits.

Two inoculation methods were tested: inclusion (with deep seeding) and membrane filtration. The inclusion seeding method has the disadvantage of having a small test sample (1 mL) compared to membrane filtration (10 mL). Since a low inoculum of microorganisms was expected in the clonidine solution to be tested, a large volume was necessary to ensure a sufficiently sensitive result. The deep seeding method makes it possible to search in particular for anaerobic and microaerobic flora. Moulds and yeasts are aerobic microorganisms and so inclusion is not suitable for them. During the inoculation of *A. brasiliensis* and *C. albicans* in depth, we noticed that these microorganisms had developed mainly on the surface and not within the agar. Moreover, microorganisms cannot be identified with the inclusion method. As regards the microbiological assessment of the clonidine solution, the contamination level after 75 days' storage is in accordance with EP criteria, with a number of CFUs below the accepted limits, and absence of pathogenic bacteria or fungi. The efficacy and advantage of using sorbate potassium in our formulation has yet to be shown, whereas it has already been proven [33]. In view of these results,

Stability of oral clonidine solution for paediatric use

1
2
3 conditions of environmental and raw-material contamination in the compounding of the
4 clonidine solution are acceptable. It is important to note that according to the EP, the
5 microbiological qualities of pharmaceutical grade substances are controlled and must be
6 stored in accordance with good practices. **There is a limitation as the analysis was made**
7 **once on each vial and not repeated after they were opened. The study does not provide data**
8 **on the re-use or contamination of the vials. With volumes of 15 mL there can be no**
9 **prolonged use of the solution. Potier A *et al.* [20] used a similar concentration of clonidine**
10 **and preservative, and did not find any stability variation when stocked or in use.**

11
12
13
14
15 Even if this work offers information about formulation and stability, data to document
16 bioavailability, pharmacokinetics, pharmacodynamics, efficacy, and tolerance profile is still
17 lacking. The aqueous solubility of clonidine of about 77 mg/mL (Merck index) ranks it in
18 either Class I (high solubility/high permeability) or Class III (high solubility/low permeability),
19 under the Biopharmaceutics Classification System [42]. **Even if permeability is reduced,**
20 **which should in theory reduce absorption, oral bioavailability is reported to be high when**
21 **used in solid oral dosage form for adults [43-44].**

22 23 24 25 26 27 28 29 **Conclusion**

30
31 This work led to the development of a 10 µg/mL clonidine solution, suitable for pediatric use,
32 and easily quantifiable through the use of a stability-indicator dosing method to determine the
33 active ingredient in a pharmaceutical preparation.

34
35
36 According to preliminary results, this solution is stable for at least 3 months when stored **at**
37 **5°C +/- 3°C** and for 1 month at room temperature.

38
39
40 The study of the microbiological contamination of a non-sterile preparation was also carried
41 out. The microbiological data obtained is satisfactory according to current recommendations.

42
43
44 The advantage of this solution as anaesthetic premedication in children must now be
45 assessed. Clinical evaluation will have to be initiated to obtain pharmacokinetic, tolerance
46 and acceptability data to establish its efficacy. The role of oral clonidine should then be
47 compared to other means, making use of other reference strategies (placebo or midazolam)
48 and / or other routes of administration (e.g.nasal route).

Stability of oral clonidine solution for paediatric use

1
2
3 **Acknowledgement**
4

5 The authors wish to thank Mrs Alexandra Tavernier, M.A. University of Glasgow, U.K.;
6
7 Professeur Agrégée, University of Lille, for her extensive revision of the final manuscript.
8
9

10
11
12
13 **Conflict of interest statement**
14

15 The authors declare that they have no conflict of interest.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

Stability of oral clonidine solution for paediatric use

1
2
3 **Bibliography**
4

5 1. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr
6 2005;164:552-8.
7

8
9 2. European Parliament. Regulation (EC) No 1901/2006 of the European Parliament and of
10 the Council of 12 December 2006 on medicinal products for paediatric use and amending
11 Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation
12 (EC) No 726/2004. Official Journal of the European Union (EU) as regulation number
13 1901/2006.
14
15
16

17
18 3. Strickley RG, Iwata Q, Wu S, Dahl TC. Pediatric drugs - a review of commercially available
19 oral formulations. J Pharm Sci 2008;97:1731-74.
20

21
22 4. Carvalho, M., Taylor, K. and Tuleu, C. Why do we need hospital pharmacy preparation ?
23 EJHP 2012;19:467-468.
24
25

26
27 5. Brayfield A. Martindale: The Complete Drug Reference 39th ed; London: Pharmaceutical
28 Press; 2017. 4792p.
29

30
31 6. Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, Li Y, Leggas M,
32 Breheny P. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics
33 2015;135:e383-91.
34
35

36
37 7. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, Lewis TR,
38 Yaster M, Gauda EB. Clonidine as an adjunct therapy to opioids for neonatal abstinence
39 syndrome: a randomized, controlled trial. Pediatrics 2009;123:e849-56.
40
41

42
43 8. Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine
44 versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal
45 abstinence syndrome. A prospective randomized clinical trial. J Perinatol 2013;33:954-9.
46
47

48
49 9. Hollis C, Pennant M, Cuenca J, Glazebrook C, Kendall T, Whittington C, Stockton S,
50 Larsson L, Bunton P, Dobson S, Groom M, Hedderly T, Heyman I, Jackson GM, Jackson S,
51 Murphy T, Rickards H, Robertson M, Stern J. Clinical effectiveness and patient perspectives
52 of different treatment strategies for tics in children and adolescents with Tourette syndrome:
53 a systematic review and qualitative analysis. Health Technol Assess 2016;20:1-450.
54
55
56

Stability of oral clonidine solution for paediatric use

1
2
3
4 10. Mastenbroel TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM. Multimodal intrathecal
5 analgesia in refractory cancer pain. *Scand J Pain* 2017;14:39-43.
6

7
8 11. Lambert P, Cyna AM, Knight N, Middleton P. Clonidine premedication for postoperative
9 analgesia in children. *Cochrane Database Syst Rev* 2014;28:CD009633.
10

11
12 12. Yeung, V.W., Wong, I.C. When do children convert from liquid antiretroviral to solid
13 formulations? *Pharm World Sci* 2005;27:399–402.
14

15
16 13. Sam T, Ernest TB, Walsh J, Williams JL. A benefit/risk approach towards selecting
17 appropriate pharmaceutical dosage forms – An application for paediatric dosage form
18 selection. *Int J Pharm* 2012;435:115-23.
19

20
21 14. European Medicines Agency: Committee for medicinal products for human use.
22 Reflection paper: formulations of choice for the paediatric population. 28 juil 2006.
23

24
25 15. de Goede AL, Boedhram RR, Eckhardt M, Hanff LM, Koch BCP, Vermaat CH, et al.
26 Development and validation of a paediatric oral formulation of clonidine hydrochloride. *Int J*
27 *Pharm* 2012;433:119-20.
28

29
30 16. Ensom MHH, Decarie D. Stability of Extemporaneously Compounded Clonidine in Glass
31 and Plastic Bottles and Plastic Syringes. *Can J Hosp Pharm* 2014;67:308-10.
32

33
34 17. Levinson ML, Johnson CE. Stability of an extemporaneously compounded clonidine
35 hydrochloride oral liquid. *Am J Hosp Pharm* 1992;49:122-125.
36

37
38 18. Ma, C, Decarie D, Ensom MHH. Stability of Clonidine Suspension in Oral Plastic
39 Syringes. *Am J Health-Syst Pharm* 2014;71:657-61.
40

41
42 19. Sauberan JB, Phuong P, Ilog ND, Rossi SS. Stability and osmolality of
43 extemporaneously prepared clonidine oral liquid for neonates. *Ann Pharmacother*
44 *2016;50:244-5*.
45

46
47 20. Potier A, Voyat J, Nicolas A. Stability study of a clonidine oral solution in a novel vehicle
48 designed for pediatric patients. *Pharm Dev Technol* 2017.
49 DOI: 10.1080/10837450.2017.138995.
50

Stability of oral clonidine solution for paediatric use

1
2
3 21. Byford JR, Shaw LE, Drew MGB, Pope GS, Sauer MJ, Darbre PD. Oestrogenic activity of
4 parabens in mcf7 human breast cancer cells. J Steroid Biochem Mol Biol 2002;80:49–60.
5

6
7 22. Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M. [the use of
8 deodorants/antiperspirants does not constitute a risk factor for breast cancer]. Bull Cancer
9 2008;95:871–880.
10

11
12
13 23. Oishi S. Effects of butylparaben on the male reproductive system in rats. Toxicol Ind
14 Health 2001;17:31–39.
15

16
17 24. Oishi S. Effects of butyl paraben on the male reproductive system in mice. Arch Toxicol
18 2002;76:423–429.
19

20
21
22 25. Tuleu C, Breitzkreutz J. Educational paper: formulation-related issues in pediatric clinical
23 pharmacology. Eur J Pediatr 2013;172:717-20.
24

25
26 26. SFPC, GERPAC. Methodological guidelines for stability studies of hospital
27 pharmaceutical preparations. 2013. Available from:
28 http://www.gerpac.eu/IMG/pdf/guide_stabilite_anglais.pdf.
29
30

31
32 27. Hubert P, Nguyen-Huu J-J, Boulanger B, Chapuzet E, Chiap P, Cohen N, et al.
33 Harmonization of strategies for the validation of quantitative analytical procedures. J Pharm
34 Biomed Anal 2007;45:70-81.
35
36

37
38 28. Hubert P, Nguyen-Huu J-J, Boulanger B, Chapuzet E, Cohen N, Compagnon P-A, et al.
39 Harmonization of strategies for the validation of quantitative analytical procedures. J Pharm
40 Biomed Anal 2007;45:82-96.
41
42

43
44 29. Hubert P, Nguyen-Huu J-J, Boulanger B, Chapuzet E, Chiap P, Cohen N, et al.
45 Harmonization of strategies for the validation of quantitative analytical procedures. J Pharm
46 Biomed Anal 2004;36:579-86.
47
48

49
50 30. Hubert P, Nguyen-Huu J-J, Boulanger B, Chapuzet E, Cohen N, Compagnon P-A, et al.
51 Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP
52 proposal. J Pharm Biomed Anal 2008;48:760-71.
53
54
55

Stability of oral clonidine solution for paediatric use

1
2
3 31. ICH Guidelines. Validation of analytical procedures: text and methodology. Q2 R1
4 2005;1. Available from: <http://somatek.com/content/uploads/2014/06/sk140605h.pdf>
5
6

7
8 32. European Pharmacopeia 9th, 2017. 5.1.4 “Microbiological quality of non-sterile
9 pharmaceutical preparations and substances for pharmaceutical use” monograph.
10

11
12 33. European Pharmacopeia 9th, 2017. 2.6.12 “microbiological examination of non-sterile
13 products: microbial enumeration tests” monograph.
14
15

16
17 34. European Pharmacopeia 9th, 2017. 2.6.13 “microbiological examination of non-sterile
18 products: tests for specified micro-organisms” monograph.
19

20
21 35. Sheskey PJ, Cook, WG, Cable, CG. Handbook of pharmaceutical excipients. Monograph
22 potassium sorbate. 8th ed. London: Pharmaceutical Press; 2017. 1216 p.
23
24

25
26 36. Classen AM, Wimbish GH, Kupiec TC. Stability of Admixture Containing Morphine
27 Sulfate, Bupivacaine Hydrochloride, and Clonidine Hydrochloride in an Implantable Infusion
28 System. J Pain and Symptom Manag 2004;28:603-11.
29

30
31 37. Hildebrand KR, Elsberry DD, Hassenbusch SJ. Stability and compatibility of morphine-
32 clonidine admixtures in an implantable infusion system. J Pain Symptom Manag
33 2003;25:464–471.
34
35

36
37 38. Shields D, Montenegro R. Chemical Stability of Ziconotide-Clonidine Hydrochloride
38 Admixtures with and without Morphine Sulfate during Simulated Intrathecal Administration.
39 Neuromodulation 2007;10:6-11.
40
41

42
43 39. Trissel LA, Xu QA, Hassenbusch SJ. Development of Clonidine Hydrochloride Injections
44 for Epidural and Intrathecal Administration. Int J Pharm Compd 1997;1:274-7.
45
46

47
48 40. Xu QA, Trissel LA, Pham L. Physical and Chemical Stability of Low and High
49 Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic
50 Syringes. Int J Pharm Compd 2002;6:66-9.
51
52

Stability of oral clonidine solution for paediatric use

1
2
3 41. Satyanarayana PVV, Adilakshmi GV. Stability indicating isocratic RP-HPLC method
4 development and validation for the simultaneous analysis of clonidine and chlorthalidone in
5 pharmaceutical formulation. Indo Am J Pharm Res 2015;5:3226-36.
6
7

8
9 42. Dahan A, Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class
10 membership: provisional BCS classification of the world's top oral drugs. AAPS
11 2009;11(4):740-6.
12
13

14
15 43. Hanning SM, Orlu Gul M, Toni I, Neubert A, Tuleu C; CloSed Consortium. A mini-review
16 of non-parenteral clonidine preparations for paediatric sedation. J Pharm Pharmacol
17 2017;69:398-405.
18
19

20
21 44. National High Blood Pressure Education Program Working Group on High Blood
22 Pressure in Children and Adolescents. U.S. Department of Health and Human Services. The
23 fourth report on the Diagnosis, evaluation, and treatment of high blood pressure in children
24 and adolescents. Pediatrics 2004;114(Supplement 2):555-576.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1: content of clonidine over 90 days at two different storage conditions

| | Storage conditions | Day 0 | Day 1 | Day 7 | Day 15 | Day 29 | Day 61 | Day 90 |
|---|--------------------|--------------|----------------|----------------|----------------|----------------|----------------|----------------|
| % initial concentration of clonidine (+/- SD) | 25°C | 100 +/- 1.28 | 99.66 +/- 0.29 | 98.35 +/- 0.71 | 95.99 +/- 0.28 | 92.95 +/- 1.28 | 86.80 +/- 0.37 | 81.82 +/- 0.41 |
| | 2-8°C | 100 +/- 1.28 | 99.41 +/- 0.22 | 99.89 +/- 0.62 | 98.68 +/- 1.58 | 97.44 +/- 1.21 | 95.96 +/- 0.48 | 93.66 +/- 0.71 |

Table 2: Osmolality and pH value over 90 days at two different storage conditions, with kruskal wallis statistical analysis

| Storage conditions | | Day 0 | Day 1 | Day 7 | Day 15 | Day 29 | Day 61 | Day 90 | Statistical analysis |
|--------------------|----------------------|-------|-------|-------|--------|--------|--------|--------|----------------------|
| 25°C | Osmolality (mOsm/kg) | 89.83 | 89.83 | 84.67 | 84.67 | 83.83 | 82.83 | 82.33 | p<0.0001 |
| | pH | 4.97 | 4.94 | 5.09 | 5.02 | 5.01 | 5.02 | 5.02 | p=0.193 |
| 2-8°C | Osmolality (mOsm/kg) | 89.83 | 92.33 | 84.00 | 83.83 | 83.33 | 82.50 | 81.50 | p=0.002 |
| | pH | 4.97 | 4.96 | 5.06 | 5.02 | 4.99 | 5.04 | 5.04 | p=0.065 |

Stability of oral clonidine solution for paediatric use

Table 3: Validation of microbial recovery method for bacteria (CFU: colony-forming unit)

| Microorganisms | | <i>E. coli</i> ATCC 25922 | | | | | | <i>S. aureus</i> ATCC 29213 | | | | | |
|--------------------------------|-----------------|-----------------------------|-------------|--------------|----------------------------|-----------------|--------------|-----------------------------|-------------|--------------|----------------------------|-----------------|--------------|
| Recovery method | | Membrane filtration (10 mL) | | | | Inclusion (1mL) | | Membrane filtration (10 mL) | | | | Inclusion (1mL) | |
| Clonidine solution | | Pure | Pure rinsed | Diluted 1/10 | Diluted at 1/10 and rinsed | Pure | Diluted 1/10 | Pure | Pure rinsed | Diluted 1/10 | Diluted at 1/10 and rinsed | Pure | Diluted 1/10 |
| Bacterial load in the solution | Mean CFU values | 316 | 268 | 284 | 261 | 46 | 43 | 292 | 309 | 318 | 285 | 34 | 34 |
| | CFU / mL | 31,6 | 26,8 | 28,4 | 26,1 | 46 | 43 | 29,2 | 30,9 | 31,8 | 28,5 | 34 | 34 |

Table 4: Validation of microbial recovery method for fungi (CFU : colony-forming unit; NQ : not quantifiable)

| Microorganisms | | <i>A. brasiliensis</i> ATCC 16404 | | | | | <i>C. albicans</i> ATCC 10231 | | | | |
|-----------------------------|-----------------|-----------------------------------|-------------|--------------|----------------------------|-----------------|-------------------------------|-------------|--------------|----------------------------|-----------------|
| Recovery method | | Membrane filtration (10 mL) | | | | Inclusion (1mL) | Membrane filtration (10 mL) | | | | Inclusion (1mL) |
| Clonidine solution | | Pure | Pure rinsed | Diluted 1/10 | Diluted at 1/10 and rinsed | Pure | Pure | Pure rinsed | Diluted 1/10 | Diluted at 1/10 and rinsed | Pure |
| Fungal load in the solution | Mean CFU values | NQ | NQ | NQ | NQ | 48 | 337 | 355 | 367 | 342 | 84 |
| | CFU / mL | NQ | NQ | NQ | NQ | 48 | 33,7 | 35,5 | 36,7 | 34,2 | 84 |

Stability of oral clonidine solution for paediatric use

Table 5: Microbial recovery after filtration of aqueous clonidine solution stored for 75 days at room temperature or at +2-8°C

| Media | 2-8°C storage | 25°C storage |
|-----------|-----------------------------|--------------|
| | Microbiological count (CFU) | |
| Sabouraud | 0 | 0 |
| PCA | 25 | 1 |
| Chapman | 0 | 25 |
| Tergitol | 15 | 1 |

For Review Only




Figure 1: Specificity of clonidine and formulation excipients

Figure 1A : chromatogram of formulation excipients (A-Potassium Citrate/Citric acid (t_r : 1.2 min); B-Saccharine (t_r : 3,4 min); C-Potassium sorbate (t_r : 16,5 min)) and clonidine (t_r : 6.06 min).

Figure 1B : Chromatogram of clonidine alone at 2.75 $\mu\text{g}/\text{mL}$ (A) (t_r = 6 min).

Separation was performed according to the analytical conditions described in the Material and Methods section.




Figure 2: Forced degradation

Chromatograms were obtained according to the optimal analytical conditions described in Chromatographic conditions in Materials and Methods section.

1) 100 µg/mL clonidine solution stocked in HCl 5N at 100°C for 3 days ; 2) 100 µg/mL clonidine solution stocked in NaOH 5N at 100°C for 3 days ; 3) 100 µg/mL clonidine solution stocked in 30% H₂O₂ at 100°C for 3 days ; 4) NaOH and HCl blank ; 5) H₂O₂ blank – A (tr = 2.9 min), B (tr = 3.4 min), C (tr = 4.2 min), D (tr = 6.5min), E (tr = 7.6 min) and F (tr = 10.9 min) are degradation products highlighted with the 100 µg/mL clonidine solutions stressed in the three different conditions (HCl 5N, NaOH 5N and 30% H₂O₂).




Figure 3: Accuracy profile of Clonidine.

The plain line corresponds to the bias. The dashed lines and dotted lines represent acceptance limits of 10% and the tolerance interval for a risk of 5%, respectively.